It’s not difficult to appreciate why the Abortion Industry, its cohorts in Congress, and its fellow travelers in the Legacy Media loathes Abortion Pill Reversal (APR). Talk about threatening a cash cow.
Over 60% of abortions in the United States are chemically induced and the idea—the menace to the Abortion Industrial Complex—that a single baby may escape the abortionist’s clutches is unfathomable, let alone thousands of babies. That’s an enormous pool of money that abortionists are not going to sacrifice without a huge struggle. Thus, the non-stop attack on abortion pill reversal as “junk science.”
But still, that having been said, it’s amazing how negatively pro-abortionists and their media colleagues react to what is, after all, a “choice.” A woman has taken the first of the two drugs that compose the “RU486” abortion technique but has had a change of heart and has chosen to try to save her baby and not take the second.
Please follow LifeNews on Rumble for the latest pro-life videos.
Not only is she attempting to right a grievous mistake, she is also much more at risk than the abortion lobby would have her believe by taking mifepristone.
Our own Dr. Randall K O’Bannon, director of Education & Research, has written extensively about the hazards of mifepristone, the abortion pill. The abortion lobby likes to quote the claim of the drug’s official label from the Food and Drug Administration (FDA) that clinical studies showed “Serious adverse reactions were reported in <0.5% of women” (one half of one percent).
However, more recent research demonstrates that mifepristone is 22 times more dangerous than advertised—that “10.93 percent of women [not one half of one percent] experience sepsis, infection, hemorrhaging, or another serious adverse event within 45 days following a mifepristone abortion,” according to Jamie Bryan Hall and Ryan T. Anderson, two researchers from the Ethics and Public Policy Center (EPPC).
Dr. O’Bannon concludes his most recent article on the dangers of mifepristone with this
Given the accelerated use to follow the FDA’s latest modification allowing pills to be mailed to homes without in-person screening or examination, and the industry’s concerted push of these abortions since Dobbs, the number of complications is sure to rise.
The new administration’s heads for Health and Human Services (HHS) and the FDA have made statements to the effect that the agency would take a look at any new data coming along that challenged the industry narrative of mifepristone’s safety and efficacy. This study should provide them with serious grounds to do so.
LifeNews.com Note: Dave Andrusko is the editor of National Right to Life News and an author and editor of several books on abortion topics. He frequently writes Today’s News and Views — an online opinion column on pro-life issues.
